GENFIT news, videos and press releases
For more news please use our advanced search feature.
GENFIT - More news...
GENFIT - More news...
- GENFIT Announces Revenues and Cash Position as of December 31, 2024
- GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
- GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
- GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
- GENFIT Reports Third Quarter 2024 Financial Information
- GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
- GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
- GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
- GENFIT: May 22, 2024 Combined Shareholders Meeting Results
- GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
- GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
- GENFIT Announces 2024 Financial Calendar
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
- Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
- GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
- GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
- GENFIT Reports Third Quarter 2023 Financial Information
- GENFIT to Participate in Upcoming Investor Conferences
- GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023
- GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
- GENFIT Reports First Quarter 2023 Financial Information
- GENFIT to Participate in Upcoming Investor Conferences
- GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
- GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®
- GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis
- GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update
- FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma
- GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)
